ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $19,000 | +11.8% | 394 | 0.0% | 0.00% | – |
| Q1 2020 | $17,000 | -65.3% | 394 | -67.2% | 0.00% | – |
| Q4 2019 | $49,000 | +36.1% | 1,200 | +20.0% | 0.00% | – |
| Q3 2019 | $36,000 | +33.3% | 1,000 | 0.0% | 0.00% | – |
| Q2 2019 | $27,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
| Q1 2019 | $27,000 | -3.6% | 1,000 | -20.0% | 0.00% | – |
| Q1 2018 | $28,000 | -26.3% | 1,250 | 0.0% | 0.00% | – |
| Q4 2017 | $38,000 | +35.7% | 1,250 | +66.7% | 0.00% | – |
| Q3 2017 | $28,000 | +33.3% | 750 | 0.0% | 0.00% | – |
| Q2 2017 | $21,000 | -69.6% | 750 | -62.5% | 0.00% | – |
| Q1 2017 | $69,000 | +19.0% | 2,000 | 0.0% | 0.00% | – |
| Q4 2016 | $58,000 | +262.5% | 2,000 | +300.0% | 0.00% | – |
| Q2 2016 | $16,000 | -42.9% | 500 | -50.0% | 0.00% | – |
| Q1 2016 | $28,000 | +33.3% | 1,000 | +66.7% | 0.00% | – |
| Q4 2015 | $21,000 | +23.5% | 600 | +20.0% | 0.00% | – |
| Q3 2015 | $17,000 | +30.8% | 500 | +66.7% | 0.00% | – |
| Q2 2015 | $13,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |